Endocrinology
Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.
Recent Discussions
Would you ever recommend radiofrequency ablation over surgery or radioiodine for a patient with an autonomously functioning thyroid nodule?
This answer can be very patient-specific, of course, in terms of preference, co-morbidities (is surgery safe), and risk of the nodule and size. I don't often do RAI for toxic adenoma /toxic MNG if the patient is a good surgical candidate or tolerates anti-thyroidals well without incident. I also hav...
What TSH cut off do you use to determine the need for levothyroxine supplementation in a pregnant patient with positive TPO antibodies?
Current ATA pregnancy guidelines recommend measuring TPO antibodies to determine the need for levothyroxine initiation in mildly hypothyroid pregnant women. However, the most recent data do not support this approach. The upcoming revision to the ATA pregnancy guidelines will no longer factor in TPO ...
What is your approach to the use of GLP-1 agonists in older adults with diabetes with or at risk of sarcopenia?
This is an important question to keep an eye on, given the broadening use and effectiveness of GLP-1 agonists for various conditions, especially diabetes, and for weight loss. Unfortunately, as is so often the case, major clinical trials in this area do not reflect the heterogeneity of older adults ...
How do you mitigate maternal cardiovascular risk in pregnant patients with known coronary artery disease who have discontinued statin therapy?
In patients with severe hypercholesterolemia, for example, who have HeFH, I have used a bile acid sequestrant during the pregnancy to at least lower their LDL about during this time. Having said that, I don’t know of any data supporting this. Patients with HoFH consideration for apheresis should be ...
When would you offer post-operative concurrent chemoradiation in anaplastic thyroid cancer?
The management of ATC has evolved considerably over recent years with the most significant being a dichotomy of management based on Braf mutation. We typically offer postoperative XRT, including in patients with either a limited or stable DM disease. However, in a multidisciplinary setting, there so...
Do you taper steroids more aggressively to decrease the risk of developing new-onset diabetes after transplantation in kidney transplant recipients who had pretransplant impaired fasting glucose?
Steroids are given after any transplant (kidney, heart, lung, bone marrow, etc.,) to reduce risk of rejection of the transplanted organ. Preservation of organ function is the number one concern for the transplant team. Steroid free regimens for anti-rejection are always a goal but the transition to ...
What is the preferred osteoporosis therapy after completing teriparatide in a young woman planning pregnancy within the next year?
It would be helpful to know the T-scores of the spine and femoral neck. I also like to have the bone remodeling markers. My recommendation would be adequate calcium intake of 1000 mg daily, preferably from diet, and 4000 IUs of vitamin D daily, not only to help preserve bone health, but vitamin D al...
How will the newer JCEM guidelines on primary aldosteronism (PA) impact your management and screening of PA?
I believe you are going to see more screening for PA and more assistance needed by healthcare providers on how to interpret the results. I also believe that perhaps this may lead to more use of steroidal MRA, which is a great thing for many patients having trouble with control of low-renin HTN.
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
While higher-intensity statins are associated with a slightly higher incidence of diabetes, it would not be recommended to start with low-intensity statins as there are no data to support this. Essentially, all of the CV outcomes trials with statins have been with moderate and high-intensity statins...
Do you plan to initiate combination therapy with an SGLT-2 inhibitor and finerenone, instead of an SGLT-2 inhibitor alone, when treating patients with proteinuric chronic kidney disease and type 2 diabetes in light of the CONFIDENCE trial findings?
I would start one (typically the SGLT-2 inhibitor), then add finerenone potentially later. If both are started simultaneously and there is an AE, then both may have to be stopped. I prefer to see that one is tolerated, then start another.